LATEST NEWS
Subcutaneous pembrolizumab demonstrates noninferiority to intravenous administration
Phase III data in metastatic NSCLC support an alternative route of administering immunotherapy, which may have an impact on patients’ preferences and cancer care costs
Perioperative durvalumab led to encouraging survival data in resectable NSCLC
An improvement was observed when immunotherapy was added to neoadjuvant chemotherapy, but further data are needed to confirm the survival benefit
Targeting KRAS G12C in NSCLC: balancing the benefit–risk profile of first-line combinations is still challenging
Studies evaluate the efficacy and safety of promising agents including adagrasib and fulzerasib
Novel ways presented to mitigate combination therapy toxicity in EGFR-mutant advanced NSCLC
Results from the ETOP AMAZE-lung and COCOON trials show some promise to improve safety and reduce skin adverse events
Promising activity reported with second-line TKIs in oncogene-addicted advanced NSCLC
Results from two trials could expand current options for patients with EGFR or HER2-activating mutations progressing on tyrosine kinase inhibitors
Is it time for pathologists to take a more active role in lung cancer?
According to Heine H. Hansen Award winner, Prof. Keith Kerr, pathologists can help translate scientific understanding into clinical practice
OPINIONS
What is the role of adjuvant immunotherapy in contemporary melanoma care?
Marco Donia
Drug de-escalation in lung cancer: are we nearly there yet?
Benjamin Besse
Tumour-agnostic drug development is revolutionising precision oncology
Vivek Subbiah
Novel insights into combination therapy in metastatic castration-resistant prostate cancer
Christoph Oing
ctDNA and beyond to serve immunotherapy
Umberto Malapelle
OPINIONS
What is the role of adjuvant immunotherapy in contemporary melanoma care?
Marco Donia
Drug de-escalation in lung cancer: are we nearly there yet?
Benjamin Besse
Tumour-agnostic drug development is revolutionising precision oncology
Vivek Subbiah
Novel insights into combination therapy in metastatic castration-resistant prostate cancer
Christoph Oing
ctDNA and beyond to serve immunotherapy
Umberto Malapelle